List of Excipients in Branded Drug OLOPATADINE HYDROCHLORIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sandoz Inc	OLOPATADINE HYDROCHLORIDE	olopatadine hydrochloride	61314-271	BENZALKONIUM CHLORIDE
Sandoz Inc	OLOPATADINE HYDROCHLORIDE	olopatadine hydrochloride	61314-271	HYDROCHLORIC ACID
Sandoz Inc	OLOPATADINE HYDROCHLORIDE	olopatadine hydrochloride	61314-271	SODIUM CHLORIDE

Generic Drugs Containing OLOPATADINE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	olopatadine hydrochloride	0093-7684	BENZALKONIUM CHLORIDE
Teva Pharmaceuticals USA Inc	olopatadine hydrochloride	0093-7684	EDETATE DISODIUM
Teva Pharmaceuticals USA Inc	olopatadine hydrochloride	0093-7684	POVIDONE K30

What are the Most Frequently-Used Excipients in OLOPATADINE HYDROCHLORIDE?

# Of NDCs	Excipient
86	BENZALKONIUM CHLORIDE
41	EDETATE DISODIUM
85	HYDROCHLORIC ACID

Olopatadine Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: August 4, 2026

Olopatadine hydrochloride is a mature ophthalmic and nasal antihistamine with limited protection from active-ingredient patents. Commercial opportunity has shifted to preservative-free delivery, multidose packaging, improved comfort, OTC positioning, nasal-device performance, and differentiated formulations. The principal excipient risks are benzalkonium chloride exposure, ocular tolerability, pH and osmolality control, container compatibility, and preservative efficacy.

What products contain olopatadine hydrochloride?

Olopatadine hydrochloride is marketed primarily in ophthalmic solutions for allergic conjunctivitis and in a nasal spray for allergic rhinitis. The active ingredient is the hydrochloride salt of olopatadine, a selective histamine H1 antagonist with mast-cell stabilizing activity.

Product or dosage form	Typical strength	Route	Commercial status
Patanol ophthalmic solution	0.1%	Eye	Mature branded and generic market
Pataday ophthalmic solution	0.2%	Eye	OTC and generic market
Pataday Once Daily Relief	0.7% olopatadine equivalent	Eye	OTC, higher-strength product
Patanase nasal spray	665 mcg per spray	Nasal	Mature branded and generic market
Generic ophthalmic solutions	Primarily 0.1% and 0.2%	Eye	Multiple abbreviated new drug application products
Generic nasal spray	665 mcg per spray	Nasal	Generic competition has developed

Patanol received FDA approval in 1996. Patanase was approved in 2008, and the higher-strength once-daily ophthalmic product was approved in 2015. FDA later approved nonprescription versions of olopatadine ophthalmic products, materially expanding the consumer market beyond prescription allergy treatment.[1-4]

What excipients are used in olopatadine hydrochloride ophthalmic products?

The conventional ophthalmic platform uses a buffered, isotonic aqueous solution with benzalkonium chloride as the preservative.

Common ophthalmic excipients

Excipient	Function	Commercial implication
Benzalkonium chloride	Antimicrobial preservative	Low cost and established regulatory history, but raises ocular-surface tolerability concerns
Sodium chloride	Tonicity adjustment	Supports comfort and ophthalmic equivalence
Dibasic sodium phosphate	Buffering agent	Controls pH and supports chemical stability
Hydrochloric acid and sodium hydroxide	pH adjustment	Enables tight pH specification
Purified water	Vehicle	Standard ophthalmic solvent
Povidone, where used	Wetting or viscosity aid	May improve retention and comfort but can affect drop delivery and feel
Edetate disodium, particularly in nasal products	Chelating agent	Supports preservative performance and may reduce metal-catalyzed degradation

Patanol and Pataday formulations historically relied on benzalkonium chloride, sodium chloride, phosphate buffer, pH adjusters, and purified water. The 0.7% product also uses a conventional aqueous ophthalmic platform, with product-specific differences in preservative and excipient levels.[1,2,5]

The key development principle is that excipients must support ophthalmic safety without changing the product's delivered dose, drop size, pH, osmolality, viscosity, or preservative performance. A formulation that is chemically stable but produces variable drop volume can create bioequivalence and labeling problems.

Which excipients create the greatest commercial opportunity?

The strongest opportunity is a preservative-free olopatadine ophthalmic product in a multidose or unit-dose presentation.

Preservative-free ophthalmic formulations

Benzalkonium chloride is effective, inexpensive, and widely accepted in short-course ophthalmic products. Repeated exposure can damage the tear film and ocular surface in susceptible patients, particularly those with dry eye, chronic allergy, contact-lens use, or frequent dosing.[6]

A preservative-free strategy could use:

• Unit-dose containers with no antimicrobial preservative.
• Multidose bottles with a mechanically sterile dispensing system.
• Low-extractable, low-sorbing polymer containers.
• Barrier packaging that controls microbial ingress.
• Aseptic filling with validated in-use sterility.

The commercial tradeoff is cost. Unit-dose packaging increases material, filling, shipping, and waste costs. Preservative-free multidose systems require a device platform, microbial robustness, and human-factors validation. The product must also demonstrate stability after repeated opening and dosing.

Alternative preservative systems

Polyquaternium-1, oxidative preservative systems, and borate-based preservative technologies may reduce ocular-surface burden compared with benzalkonium chloride. Each alternative creates a new development package involving preservative efficacy, toxicology, container compatibility, extractables and leachables, and comparative ocular tolerability.

Replacing benzalkonium chloride is not automatically commercially advantageous. A new preservative can create a regulatory differentiation point only if it produces a meaningful patient benefit or enables a premium presentation.

Comfort-focused excipient systems

A small amount of povidone or another ophthalmic-grade polymer can improve wetting and reduce transient discomfort. Excessive viscosity can cause blurred vision, affect drop retention, or produce a different pharmacokinetic profile.

The most commercially useful design target is usually a modest comfort improvement without a large increase in viscosity. A high-viscosity product may be more difficult to establish as therapeutically equivalent to a reference solution.

What formulations are protected by olopatadine patents?

The original olopatadine molecule and early formulations are mature intellectual property. The main patent opportunity is no longer basic composition-of-matter protection.

Potentially protectable features include:

1. Preservative-free olopatadine solutions.
2. Multidose sterile dispensing systems.
3. Specific pH and osmolality windows.
4. Stability solutions for high-concentration olopatadine.
5. Low-irritation preservative combinations.
6. Contact-lens-compatible formulations.
7. Combination products with lubricants or other allergy agents.
8. Nasal suspensions, solutions, or particle-size distributions.
9. Spray-pump designs that control plume geometry and delivered dose.
10. Manufacturing processes that reduce degradation or particulate formation.

How strong is the patent estate for olopatadine hydrochloride?

The core patent estate is weak for blocking generic entry because the active ingredient, conventional dosage forms, and major branded products have been commercially available for many years. Formulation and device patents may still support narrower exclusivity, but they generally do not prevent approval of a conventional generic solution.

A follow-on applicant should expect greater patent value from:

• A genuinely distinct preservative-free platform.
• A proprietary bottle or spray pump.
• A new combination product.
• A clinically supported tolerability advantage.
• A use patent tied to a defined patient group or dosing schedule.

The enforceability of such patents depends on claim scope. A patent directed only to routine pH adjustment, standard buffers, or predictable preservative substitution is more vulnerable to obviousness challenges than a patent tied to unexpected stability, improved tolerability, or device-dependent performance.

When does olopatadine hydrochloride lose exclusivity?

Olopatadine hydrochloride has already lost the exclusivity associated with its original branded products. The current market is defined by generic competition, OTC competition, and product-level differentiation rather than by NCE exclusivity.

Exclusivity category	Current commercial position
Composition-of-matter protection	Expired or commercially exhausted
Original product exclusivity	Expired
Conventional ophthalmic solution protection	Insufficient to block standard generics
Nasal-spray exclusivity	Mature, with generic competition
OTC monograph or switch-based opportunity	Available for qualifying ophthalmic products
Biosimilar exclusivity	Not applicable

Patent expiration dates must be assessed patent by patent and jurisdiction by jurisdiction. The relevant commercial question is not whether an old olopatadine patent remains listed, but whether a live claim covers the proposed strength, formulation, container, method of use, or device.

What is the Orange Book status of olopatadine hydrochloride?

FDA Orange Book treatment is product-specific. Olopatadine ophthalmic products may have listed patents associated with branded products, but standard generic approval is generally based on the reference product's dosage form, strength, route, and therapeutic equivalence requirements.

For a commercial assessment, the Orange Book review should separate:

• Patanol 0.1% ophthalmic solution.
• Pataday 0.2% ophthalmic solution.
• Pataday 0.7% ophthalmic solution.
• Any listed formulation or method-of-use patents.
• Patent certifications submitted in ANDA approvals.
• Whether a listed patent has expired, been delisted, or remains relevant to a proposed product.

The 0.7% product warrants separate analysis because its concentration, dosing frequency, and product-specific formulation may create a different regulatory and patent profile from 0.1% and 0.2% solutions. A generic applicant cannot assume that approval of a lower-strength product resolves the technical or legal issues for the higher-strength product.

Which companies are challenging olopatadine hydrochloride products?

Generic manufacturers have entered the olopatadine ophthalmic market through ANDA pathways. The competitive field includes established ophthalmic generic companies, specialty pharmaceutical manufacturers, and companies using contract development and manufacturing organizations.

The principal competitive groups are:

• Large generic companies with sterile ophthalmic capacity.
• Specialty ophthalmology companies with branded or OTC portfolios.
• Consumer-health companies pursuing nonprescription allergy products.
• Device companies supplying preservative-free multidose dispensers.
• Contract manufacturers with aseptic fill-finish and ophthalmic packaging capabilities.

Paragraph IV risk is most relevant when a company seeks approval before expiration of a listed formulation, method-of-use, or device patent. For a conventional olopatadine solution, the commercial threat from a Paragraph IV filing is usually greater than the value of defending old composition patents, because multiple alternative formulations can reach the same therapeutic market.

What patent litigation affects olopatadine hydrochloride?

Olopatadine litigation has historically been less commercially significant than litigation involving high-value chronic therapies. The active ingredient is old, and conventional ophthalmic products have faced generic substitution.

Current litigation analysis should focus on:

• ANDA filings for high-strength or once-daily products.
• Preservative-free formulation patents.
• Device patents covering multidose dispensing.
• Nasal spray pump and plume patents.
• Settlement agreements that delay generic launch.
• Paragraph IV notices involving branded ophthalmic products.

A settlement may include a licensed entry date, authorized generic arrangements, restrictions on product launch, or a covenant not to sue. Such agreements can alter the practical launch date even when a patent remains formally unexpired.

What FDA regulatory strategy applies to olopatadine hydrochloride?

For a conventional ophthalmic solution, the principal route is an ANDA demonstrating pharmaceutical equivalence and bioequivalence or other FDA-accepted equivalence evidence. The product must match the reference drug in active ingredient, dosage form, route, strength, and applicable performance characteristics.[7]

A differentiated product may require a 505(b)(2) application when it relies on a new formulation, new delivery system, new preservative approach, or new clinical claim. The 505(b)(2) pathway can support commercial differentiation but usually requires more development work than an ANDA.

Key FDA development controls

A strong development program should control:

• Assay and degradation products.
• pH and osmolality.
• Drop size and delivered volume.
• Sterility and particulate matter.
• Preservative content over shelf life.
• Antimicrobial effectiveness.
• Container closure integrity.
• Extractables and leachables.
• In-use stability.
• Ocular irritation and tolerability.
• Device reproducibility across bottle orientation and fill level.

For nasal spray products, the control strategy expands to plume geometry, spray pattern, priming and repriming, droplet-size distribution, pump force, microbial quality, and dose uniformity. FDA guidance treats nasal spray performance as a combination of formulation and device behavior, which makes excipient and packaging decisions inseparable from regulatory strategy.[8]

How does olopatadine compare with competing allergy drugs?

Product	Active ingredient	Main differentiation	Excipient opportunity
Olopatadine	Olopatadine HCl	Antihistamine and mast-cell stabilization	Preservative-free, comfort, high-strength and device differentiation
Ketotifen	Ketotifen fumarate	Low-cost OTC antihistamine	Similar preservative-free and comfort opportunities
Alcaftadine	Alcaftadine	Once-daily ophthalmic allergy treatment	Premium dosing and tolerability positioning
Bepotastine	Bepotastine besilate	Prescription ophthalmic positioning	Formulation and dosing differentiation
Cromolyn	Cromolyn sodium	Mast-cell stabilization	Lower-cost and preservative-free positioning

Olopatadine's strongest competitive advantage is its established efficacy, broad physician familiarity, and OTC availability. Its main weakness is that conventional preserved solutions are relatively easy to copy. Commercial differentiation therefore depends on patient experience, convenience, packaging, and retail execution.

What generic launch risks exist for olopatadine hydrochloride?

A generic launch can occur through several routes:

Conventional generic solution

This is the lowest-cost and highest-volume strategy. It faces price erosion and limited brand loyalty. The formulation must closely match the reference product's performance, and the applicant gains little protection from a standard excipient profile.

Preservative-free generic or follow-on product

This strategy targets chronic users, dry-eye patients, contact-lens wearers, and consumers seeking "gentler" products. It can support premium pricing but carries greater packaging and sterility risk.

High-strength once-daily product

A 0.7% product can support convenience-based positioning. The main risks are formulation tolerability, equivalence, concentration-related irritation, and patent claims directed to the product or dosing regimen.

Nasal spray

The nasal market offers device-driven differentiation, but pump performance and suspension or solution uniformity can create manufacturing barriers. A company without internal spray-device expertise may depend on a specialized supplier.

What manufacturing and IP barriers matter most?

The active ingredient is not the principal barrier. Sterile manufacturing and packaging are.

The most important barriers are:

• Validated aseptic processing.
• Sterile filtration and fill-finish capability.
• Low-particulate manufacturing.
• Reliable ophthalmic container systems.
• Preservative-free multidose technology.
• Nasal pump qualification.
• Container closure integrity.
• Supply of high-purity ophthalmic-grade excipients.
• Control of extractables and leachables.
• Stability in commercial packaging.

These barriers can create practical market protection even when patent protection is narrow. A proprietary dispenser, reliable sterile supply chain, or high-yield fill-finish process can reduce competition without providing formal exclusivity.

What licensing deals are commercially relevant?

Licensing value is concentrated in delivery technologies rather than olopatadine itself. Attractive targets include:

• Preservative-free multidose ophthalmic systems.
• Unit-dose filling and packaging platforms.
• Low-sorption polymer containers.
• Nasal spray pumps with controlled plume performance.
• Combination ophthalmic delivery systems.
• OTC commercialization rights in selected territories.
• Regional rights to established sterile manufacturing capacity.

An olopatadine license should be evaluated against the remaining market life, expected generic price erosion, regulatory pathway, and device exclusivity. A license limited to a standard olopatadine solution has low strategic value. A license covering a validated preservative-free platform or a differentiated OTC product can support a higher-margin opportunity.

What geographic markets offer the best opportunities?

The United States offers the largest opportunity for OTC ophthalmic products and premium preservative-free presentations. Europe and Japan have established allergy markets but require country-specific regulatory, reimbursement, and packaging strategies. Emerging markets may favor low-cost generic solutions, while affluent urban markets are more receptive to preservative-free and convenience products.

Geographic priorities should be based on:

• OTC access.
• Allergy prevalence and seasonality.
• Generic substitution rules.
• Local sterile manufacturing costs.
• Regulatory acceptance of novel excipients or devices.
• Retail pharmacy concentration.
• Pricing of preservative-free products.

What is the revenue exposure for olopatadine products?

Revenue exposure is concentrated in ophthalmic products, particularly OTC allergy drops. Conventional generic products face rapid price competition, while branded OTC products can preserve value through advertising, shelf placement, dosing convenience, and consumer recognition.

A differentiated product can improve economics through:

• Once-daily dosing.
• Preservative-free labeling.
• Comfort claims supported by clinical data.
• Contact-lens user targeting.
• Premium bottle design.
• Seasonal allergy bundles.
• Retail and e-commerce distribution.
• Combination with ocular lubricants.

The most defensible commercial position is a premium, preservative-free, once-daily ophthalmic product supported by a proprietary multidose dispenser and strong consumer-health distribution.

Key Takeaways

• Olopatadine hydrochloride is a mature small-molecule market with no meaningful biosimilar issue.
• Core active-ingredient and conventional formulation protection has largely expired.
• Benzalkonium chloride is the central excipient issue because of ocular-surface tolerability concerns.
• Preservative-free multidose delivery is the leading formulation opportunity.
• Unit-dose packaging is simpler technically but less efficient commercially.
• High-strength and once-daily products require separate technical, regulatory, and patent analysis.
• Nasal spray opportunities depend heavily on pump performance and device control.
• The strongest patent claims are likely to cover delivery systems, preservative-free formulations, stability, or defined clinical use cases.
• Generic applicants face sterile manufacturing and packaging barriers more than active-ingredient barriers.
• The best commercial strategy combines excipient differentiation with OTC positioning, device ownership, and premium consumer-health distribution.

FAQs

Is olopatadine hydrochloride compatible with benzalkonium chloride?

Yes. Conventional olopatadine ophthalmic products use benzalkonium chloride as a preservative. The commercial concern is repeated ocular exposure, not basic formulation incompatibility.

Can olopatadine hydrochloride be formulated without phosphate buffer?

Yes. Alternative buffering systems may be possible, but the product must maintain acceptable pH, stability, comfort, osmolality, and preservative performance. A buffer change can also affect equivalence and regulatory comparability.

Is a preservative-free olopatadine product patentable?

Potentially. Patentability is stronger when the formulation includes a defined multidose sterile system, unexpected stability, improved tolerability, or a non-obvious combination of excipients and container technology.

Does olopatadine hydrochloride require a biosimilar application?

No. Olopatadine hydrochloride is a chemically synthesized small molecule. Generic products use the ANDA pathway, while materially changed formulations may use a 505(b)(2) application.

What is the highest-value excipient opportunity for olopatadine?

A preservative-free, once-daily ophthalmic solution delivered through a validated multidose sterile container is the leading opportunity. It addresses tolerability, convenience, and premium OTC positioning at the same time.

References

1. U.S. Food and Drug Administration. (1996). Patanol (olopatadine hydrochloride ophthalmic solution) prescribing information.

2. U.S. Food and Drug Administration. (2015). Pataday (olopatadine hydrochloride ophthalmic solution) prescribing information.

3. U.S. Food and Drug Administration. (2008). Patanase (olopatadine hydrochloride nasal spray) prescribing information.

4. U.S. Food and Drug Administration. (2020). FDA approves first over-the-counter eye drop for itch relief associated with allergies.

5. DailyMed. (n.d.). Olopatadine hydrochloride ophthalmic solution and nasal spray labeling. National Library of Medicine.

6. Baudouin, C., Aragona, P., Messmer, E. M., Tomlinson, A., Calonge, M., Boboridis, K. G., Akova, Y. A., Geerling, G., Labetoulle, M., & Rolando, M. (2013). Role of hyperosmolarity in the pathogenesis and management of dry eye disease. Progress in Retinal and Eye Research, 36, 266-285.

7. U.S. Food and Drug Administration. (2009). Guidance for industry: Bioavailability and bioequivalence studies for nasal aerosols and nasal sprays for local action.

8. U.S. Food and Drug Administration. (2022). Draft guidance for industry: Quality considerations for topical ophthalmic drug products.